<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657409</url>
  </required_header>
  <id_info>
    <org_study_id>TCGHUROL003</org_study_id>
    <nct_id>NCT01657409</nct_id>
  </id_info>
  <brief_title>Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome</brief_title>
  <official_title>Comparison of the Therapeutic Effects of Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Buddhist Tzu Chi General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overactive bladder (OAB) is a symptom syndrome characterized by urgency frequency with or
      without urge urinary incontinence (UUI) that may affect the patients' quality of life.
      Current medical treatments are usually unsuccessful in completely eradicating urgency
      sensation. Intra-detrusor injection of botulinum toxin A (BoNT-A) modulates the release of
      neurotransmitters from sensory nerve endings and effectively modulates the inflammatory
      process mediated by nociceptive afferent nerve dysfunction. Satisfactory clinical results
      were achieved with intravesical BoNT-A injection, which increased bladder capacity and
      decreased urgency sensation in patients with neurogenic or idiopathic detrusor overactivity
      (NDO, IDO). Excellent results were achieved with injection of either 100 U or 200 U of
      BoNT-A. Episodes of frequency, urgency, and UUI were reduced, maximal cystometric capacity
      increased, maximal detrusor pressure (Pdet) decreased, and the quality of life index also
      improved significantly. However, post void residual (PVR) volume increased significantly and
      some patients required clean intermittent catheterization (CIC) to evacuate the PVR.
      Dose-related adverse events (AE) increased with increasing dose of BoNT-A. Therefore,
      adjustments of the BoNT-A dose and sites of injection might minimize the de novo AE and help
      to maintain success rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed as a single blind, randomized, parallel, actively controlled trial.
      The urodynamic DO confirmed patients were randomly assigned to receive injection of
      onabotulinumtoxinA 100 U (BoNT-A, Allergan, Irvine, California, USA), which was reconstituted
      to 10 ml with normal saline for suburothelial injections, in one of the three groups with the
      following injection number: (A) 100 U in 10ml injections, 1.0ml for each injection, totally
      10 injections at bladder body (B) 100 U in 10ml, 0.5ml for each injection, totally 20
      injections at bladder body, (C) 100 U in 10ml, 0.25ml for each injection, totally 40
      injections at bladder body. Permuted block randomization was used for this trial. All
      treatments were evaluated at baseline and the primary end-point at 3 months.

      The inclusion criteria were patients of either gender, aged 20 years or more, with urodynamic
      DO and at least one episode of urgency (urgency severity scale, USS≥2) or UUI per day as
      recorded in the 3-day voiding diary. Patients with neurogenic bladder, urodynamically
      confirmed bladder outlet obstruction, prior pelvic surgery, anti-incontinence surgery or
      urinary tract infection (UTI, white blood cell(WBC)&gt;10/high power field (HPF) in urinalysis)
      were excluded. Informed consent was obtained from all patients before randomization. This
      study should be approved by the Institution Review Board and Ethics Committee of the
      hospital.

      All patients had been managed with behavioral modification and treated with a certain number
      of antimuscarinics for more than 4 weeks before they were enrolled into this trial.
      Antimuscarinics was discontinued on the day of screening to wash out the remaining effect and
      obtaining a voiding diary that may reflect the true bladder condition.

      The injection method for each patient was not recorded in the operation note and the study
      nurse who controlled the outcome measures was blinded to the treatment assignment. All
      procedures were performed transurethrally under intravenous general anesthesia in the
      operation room. Anticoagulant was discontinued 1 week prior to onabotulinumtoxinA treatment.
      The bladder volume was kept at 100-150 ml and the blood vessels were avoided during
      injections. An indwelling Foley catheter was placed in the bladder overnight and the patients
      were discharged the next morning. Broad-spectrum prophylactic antibiotics were given
      postoperatively for 3 days. Patients who developed acute urinary retention (AUR) or PVR
      volumes greater than 250 ml were advised to perform CIC periodically to evacuate their
      bladders. The patients were monitored at the outpatient clinic regularly for upto 24 months
      until symptoms returned to baseline levels.

      Videourodynamic study was routinely performed at baseline, 3 and 6 months to measure
      urodynamic variables and detecting vesicoureteral reflux. The measured urodynamic variables
      included: maximum flow rate (Qmax), PVR, cystometric bladder capacity (CBC), detrusor
      pressure at Qmax (Pdet) and voiding efficiency (VE). The procedure and definition of
      videourodynamic study were in accordance of the recommendations of the International
      Continence Society.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients were randomized to receive different injection number of onabotulinumtoxinA</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants did not aware how many injections were performed</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Global response assessment (GRA) of satisfaction by the patient</measure>
    <time_frame>2 weeks after initial treatment</time_frame>
    <description>GRA (-3, -2, -1, 0, +1, +2, +3) of satisfaction by the patient
GRA≥+1: Respond
GRA≤0: Non-respond</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Voiding and urodynamic parameters</measure>
    <time_frame>2 weeks after the initial treatment day</time_frame>
    <description>Overactive bladder symptom score (OABSS)
Urgency severity score (USS)
Urgency urinary incontinence (UUI)/3 days
Urodynamic parameters
Functional bladder capacity (FBC)
Maximum flow rate (Qmax)
Postvoid residual volume (PVR)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>BoNT-A (10 injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 U in 10ml, 1.0ml for each injection, totally 10 injections at bladder body</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BoNT-A (20 injections)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 U in 10ml, 0.5ml for each injection, totally 20 injections at bladder body</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BoNT-A (40 injections)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 U in 10ml, 0.25ml for each injection, totally 40 injections at bladder body</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BoNT-A (10 injection)</intervention_name>
    <description>BoNT-A 100 U 10 injections</description>
    <arm_group_label>BoNT-A (10 injection)</arm_group_label>
    <other_name>Botulinum Toxin A (Botox)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BoNT-A (20 injection)</intervention_name>
    <description>BoNT-A 100 U 20 injections</description>
    <arm_group_label>BoNT-A (20 injections)</arm_group_label>
    <other_name>Botulinum Toxin A (Botox)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BoNT-A (40 injection)</intervention_name>
    <description>BoNT-A 100 U 40 injections</description>
    <arm_group_label>BoNT-A (40 injections)</arm_group_label>
    <other_name>Botulinum Toxin A (Botox)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The inclusion criteria were patients of either gender, aged 20 years or more, with
             urodynamic DO and at least one episode of urgency (urgency severity scale, USS≥2) or
             UUI per day as recorded in the 3-day voiding diary. Patients with neurogenic bladder,
             urodynamically confirmed bladder outlet obstruction, prior pelvic surgery,
             anti-incontinence surgery or urinary tract infection (UTI, white blood cell (WBC)
             &gt;10/high power field (HPF) in urinalysis) were excluded. Informed consent was obtained
             from all patients before randomization. This study should be approved by the
             Institution Review Board and Ethics Committee of the hospital.

        Exclusion Criteria:

          -  Use of antimuscarinic agent and effective in treatment of lower urinary tract symptoms

          -  Patients with severe cardiopulmonary disease and such as congestive heart failure,
             arrhythmia, poorly controlled hypertension, not able to receive regular follow-up

          -  Patients with bladder outlet obstruction on enrollment

          -  Patients with postvoid residual &gt; 150ml

          -  Patients with uncontrolled confirmed diagnosis of acute urinary tract infection

          -  Patients have laboratory abnormalities at screening including:

          -  Alanine aminotransferase (ALT)&gt; 3 x upper limit of normal range

          -  Aspartate aminotransferase (AST)&gt; 3 x upper limit of normal range

          -  Patients have abnormal serum creatinine level &gt; 2 x upper limit of normal range

          -  Patients with any contraindication to be urethral catheterization during treatment

          -  Female patients who is pregnant, lactating, or with child-bearing potential without
             contraception.

          -  Myasthenia gravis, Eaton Lambert syndrome.

          -  Patients with any other serious disease considered by the investigator not suitable
             for general anesthesia or in the condition to enter the trial Patients participated
             investigational drug trial within 1 month before entering this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hann-Chorng Kuo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000 Jul;6(11 Suppl):S580-90. Review.</citation>
    <PMID>11183901</PMID>
  </reference>
  <reference>
    <citation>Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006 Jan;97(1):96-100.</citation>
    <PMID>16336336</PMID>
  </reference>
  <reference>
    <citation>Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 Jun;87(9):760-6. Erratum in: BJU Int 2001 Nov;88(7):807.</citation>
    <PMID>11412210</PMID>
  </reference>
  <reference>
    <citation>Chen GD, Lin TL, Hu SW, Chen YC, Lin LY. Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. Neurourol Urodyn. 2003;22(2):109-17.</citation>
    <PMID>12579627</PMID>
  </reference>
  <reference>
    <citation>Homma Y, Yamaguchi O, Hayashi K; Neurogenic Bladder Society Committee. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005 Dec;96(9):1314-8.</citation>
    <PMID>16287452</PMID>
  </reference>
  <reference>
    <citation>Kullmann FA, Artim DE, Birder LA, de Groat WC. Activation of muscarinic receptors in rat bladder sensory pathways alters reflex bladder activity. J Neurosci. 2008 Feb 20;28(8):1977-87. doi: 10.1523/JNEUROSCI.4694-07.2008.</citation>
    <PMID>18287514</PMID>
  </reference>
  <reference>
    <citation>Mukerji G, Yiangou Y, Grogono J, Underwood J, Agarwal SK, Khullar V, Anand P. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 2006 Jul;176(1):367-73.</citation>
    <PMID>16753445</PMID>
  </reference>
  <reference>
    <citation>Ouslander JG. Management of overactive bladder. N Engl J Med. 2004 Feb 19;350(8):786-99. Review.</citation>
    <PMID>14973214</PMID>
  </reference>
  <reference>
    <citation>Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment for urinary incontinence in women. A Cochrane systematic review. Eur J Phys Rehabil Med. 2008 Mar;44(1):47-63. Review.</citation>
    <PMID>18385628</PMID>
  </reference>
  <reference>
    <citation>Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther. 1980 Jan;212(1):16-21.</citation>
    <PMID>6243359</PMID>
  </reference>
  <reference>
    <citation>Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005 Sep;174(3):977-82; discussion 982-3.</citation>
    <PMID>16094018</PMID>
  </reference>
  <reference>
    <citation>Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003 Jul-Aug;43 Suppl 1:S9-15. Review.</citation>
    <PMID>12887389</PMID>
  </reference>
  <reference>
    <citation>Yiangou Y, Facer P, Ford A, Brady C, Wiseman O, Fowler CJ, Anand P. Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int. 2001 Jun;87(9):774-9.</citation>
    <PMID>11412212</PMID>
  </reference>
  <reference>
    <citation>Avelino A, Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol. 2006 Jul;373(4):287-99. Epub 2006 May 24. Review.</citation>
    <PMID>16721555</PMID>
  </reference>
  <reference>
    <citation>Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005 Sep;174(3):984-9.</citation>
    <PMID>16094019</PMID>
  </reference>
  <reference>
    <citation>Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology. 2004 May;63(5):868-72.</citation>
    <PMID>15134967</PMID>
  </reference>
  <reference>
    <citation>Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007 Jun;177(6):2231-6.</citation>
    <PMID>17509328</PMID>
  </reference>
  <reference>
    <citation>Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J; Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008 Jul;180(1):217-22. doi: 10.1016/j.juro.2008.03.028. Epub 2008 May 21.</citation>
    <PMID>18499184</PMID>
  </reference>
  <reference>
    <citation>Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004 Apr;45(4):510-5.</citation>
    <PMID>15041117</PMID>
  </reference>
  <reference>
    <citation>Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn. 2005;24(3):231-6.</citation>
    <PMID>15747344</PMID>
  </reference>
  <reference>
    <citation>Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int. 2005 Oct;96(6):848-52.</citation>
    <PMID>16153215</PMID>
  </reference>
  <reference>
    <citation>Schulte-Baukloh H, Weiss C, Stolze T, Stürzebecher B, Knispel HH. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology. 2005 Jul;66(1):82-7.</citation>
    <PMID>15992872</PMID>
  </reference>
  <reference>
    <citation>Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology. 2005 Jul;66(1):94-8.</citation>
    <PMID>15992869</PMID>
  </reference>
  <reference>
    <citation>Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, Shah PJ, Malone-Lee J. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 2005 Nov;174(5):1873-7; discussion 1877.</citation>
    <PMID>16217327</PMID>
  </reference>
  <reference>
    <citation>Sahai A, Sangster P, Kalsi V, Khan MS, Fowler CJ, Dasgupta P. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable? BJU Int. 2009 Mar;103(5):630-4. doi: 10.1111/j.1464-410X.2008.08076.x. Epub 2008 Oct 16.</citation>
    <PMID>18990156</PMID>
  </reference>
  <reference>
    <citation>White WM, Pickens RB, Doggweiler R, Klein FA. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol. 2008 Dec;180(6):2522-6. doi: 10.1016/j.juro.2008.08.030. Epub 2008 Oct 19.</citation>
    <PMID>18930481</PMID>
  </reference>
  <reference>
    <citation>Brady CM, Apostolidis AN, Harper M, Yiangou Y, Beckett A, Jacques TS, Freeman A, Scaravilli F, Fowler CJ, Anand P. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int. 2004 Apr;93(6):770-6.</citation>
    <PMID>15049988</PMID>
  </reference>
  <reference>
    <citation>Brady CM, Apostolidis A, Yiangou Y, Baecker PA, Ford AP, Freeman A, Jacques TS, Fowler CJ, Anand P. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol. 2004 Aug;46(2):247-53.</citation>
    <PMID>15245821</PMID>
  </reference>
  <reference>
    <citation>Smet PJ, Moore KH, Jonavicius J. Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest. 1997 Jul;77(1):37-49.</citation>
    <PMID>9251677</PMID>
  </reference>
  <reference>
    <citation>Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004 Mar;63(3 Suppl 1):17-23. Review.</citation>
    <PMID>15013648</PMID>
  </reference>
  <reference>
    <citation>Apostolidis A, Brady CM, Yiangou Y, Davis J, Fowler CJ, Anand P. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology. 2005 Feb;65(2):400-5.</citation>
    <PMID>15708075</PMID>
  </reference>
  <reference>
    <citation>Wiseman OJ, Fowler CJ, Landon DN. The role of the human bladder lamina propria myofibroblast. BJU Int. 2003 Jan;91(1):89-93.</citation>
    <PMID>12614258</PMID>
  </reference>
  <reference>
    <citation>Sui GP, Rothery S, Dupont E, Fry CH, Severs NJ. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int. 2002 Jul;90(1):118-29.</citation>
    <PMID>12081783</PMID>
  </reference>
  <reference>
    <citation>Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006 Apr;49(4):644-50. Epub 2006 Jan 4. Review.</citation>
    <PMID>16426734</PMID>
  </reference>
  <reference>
    <citation>Tyagi P, Wu PC, Chancellor M, Yoshimura N, Huang L. Recent advances in intravesical drug/gene delivery. Mol Pharm. 2006 Jul-Aug;3(4):369-79. Review.</citation>
    <PMID>16889430</PMID>
  </reference>
  <reference>
    <citation>Giannantoni A, Di Stasi SM, Chancellor MB, Costantini E, Porena M. New frontiers in intravesical therapies and drug delivery. Eur Urol. 2006 Dec;50(6):1183-93; discussion 1193. Epub 2006 Aug 30. Review.</citation>
    <PMID>16963179</PMID>
  </reference>
  <reference>
    <citation>Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol. 2008 Mar;179(3):1031-4. doi: 10.1016/j.juro.2007.10.032. Epub 2008 Jan 18.</citation>
    <PMID>18206941</PMID>
  </reference>
  <reference>
    <citation>Kuo HC, Liu HT, Yang WC. Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. J Urol. 2006 Aug;176(2):641-5.</citation>
    <PMID>16813911</PMID>
  </reference>
  <reference>
    <citation>Birder LA. More than just a barrier: urothelium as a drug target for urinary bladder pain. Am J Physiol Renal Physiol. 2005 Sep;289(3):F489-95. Review.</citation>
    <PMID>16093424</PMID>
  </reference>
  <reference>
    <citation>Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol. 2004 Oct;172(4 Pt 1):1529-32.</citation>
    <PMID>15371885</PMID>
  </reference>
  <reference>
    <citation>Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2009 Oct;56(4):700-6. doi: 10.1016/j.eururo.2008.04.037. Epub 2008 Apr 30.</citation>
    <PMID>18472208</PMID>
  </reference>
  <reference>
    <citation>Atiemo H, Wynes J, Chuo J, Nipkow L, Sklar GN, Chai TC. Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology. 2005 Mar;65(3):622-6.</citation>
    <PMID>15780404</PMID>
  </reference>
  <reference>
    <citation>Crowley SL, Worchel FF, Ash MJ. Self-report, peer-report, and teacher-report measures of childhood depression: an analysis by item. J Pers Assess. 1992 Aug;59(1):189-203.</citation>
    <PMID>1512677</PMID>
  </reference>
  <reference>
    <citation>Vemulakonda VM, Somogyi GT, Kiss S, Salas NA, Boone TB, Smith CP. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol. 2005 Feb;173(2):621-4.</citation>
    <PMID>15643276</PMID>
  </reference>
  <reference>
    <citation>Fraser MO, Chuang YC, Tyagi P, Yokoyama T, Yoshimura N, Huang L, De Groat WC, Chancellor MB. Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat. Urology. 2003 Mar;61(3):656-63.</citation>
    <PMID>12639679</PMID>
  </reference>
  <reference>
    <citation>Chuang YC, Tyagi P, Huang CC, Yoshimura N, Wu M, Kaufman J, Chancellor MB. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol. 2009 Aug;182(2):786-92. doi: 10.1016/j.juro.2009.03.083. Epub 2009 Jun 18.</citation>
    <PMID>19539320</PMID>
  </reference>
  <reference>
    <citation>Reimer K, Fleischer W, Brögmann B, Schreier H, Burkhard P, Lanzendörfer A, Gümbel H, Hoekstra H, Behrens-Baumann W. Povidone-iodine liposomes--an overview. Dermatology. 1997;195 Suppl 2:93-9. Review.</citation>
    <PMID>9403264</PMID>
  </reference>
  <reference>
    <citation>Egerdie RB, Reid G, Trachtenberg J. The effect of liposome encapsulated antineoplastic agents on transitional cell carcinoma in tissue culture. J Urol. 1989 Aug;142(2 Pt 1):390-8.</citation>
    <PMID>2501520</PMID>
  </reference>
  <reference>
    <citation>Tyagi P, Chancellor MB, Li Z, De Groat WC, Yoshimura N, Fraser MO, Huang L. Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol. 2004 Jan;171(1):483-9.</citation>
    <PMID>14665960</PMID>
  </reference>
  <reference>
    <citation>Chuang YC, Lee WC, Lee WC, Chiang PH. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009 Oct;182(4):1393-400. doi: 10.1016/j.juro.2009.06.024. Epub 2009 Aug 15.</citation>
    <PMID>19683290</PMID>
  </reference>
  <reference>
    <citation>Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007 Sep;70(3):463-8.</citation>
    <PMID>17905097</PMID>
  </reference>
  <reference>
    <citation>Truschel ST, Wang E, Ruiz WG, Leung SM, Rojas R, Lavelle J, Zeidel M, Stoffer D, Apodaca G. Stretch-regulated exocytosis/endocytosis in bladder umbrella cells. Mol Biol Cell. 2002 Mar;13(3):830-46.</citation>
    <PMID>11907265</PMID>
  </reference>
  <reference>
    <citation>Wang E, Truschel S, Apodaca G. Analysis of hydrostatic pressure-induced changes in umbrella cell surface area. Methods. 2003 Jul;30(3):207-17.</citation>
    <PMID>12798135</PMID>
  </reference>
  <reference>
    <citation>Cui M, Aoki KR. Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia 20:414-8, 2000.</citation>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Buddhist Tzu Chi General Hospital</investigator_affiliation>
    <investigator_full_name>Hann-Chorng Kuo</investigator_full_name>
    <investigator_title>Department of Urology</investigator_title>
  </responsible_party>
  <keyword>botulinum toxin</keyword>
  <keyword>detrusor overactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

